Peter DiLaura

Peter DiLaura is currently the President, Chief Executive Officer & Director at Initial Therapeutics Inc. He is also a Director at Character Biosciences, Inc., an Executive-in-Residence at ShangPharma Innovation, Inc., and a Venture Partner at Lifeforce Capital Management, LLC.
In the past, Mr. DiLaura served as the President, Chief Executive Officer & Director at Second Genome, Inc. from 2012 to 2016.
He was also the Director of Business Development at Ventro Corp.
from 1999 to 2001.
Additionally, he held a position in business development at International Business Machines Corp.
Mr. DiLaura was a Strategic Advisor at SV Health Investors LLP from 2017 to 2019.
He was the Senior Vice President of Products & Marketing at Ingenuity Systems, Inc. in 2010.
He also served as an Advisor at Takeda Pharmaceutical Co., Ltd. in 2017.
Furthermore, Mr. DiLaura worked as a Principal at Wilkerson Group and as the Chief Business & Strategy Officer at Sonoma Biotherapeutics, Inc. Mr. DiLaura completed his undergraduate degree at the University of Pennsylvania in 1995.
He also received an undergraduate degree from The Wharton School of the University of Pennsylvania in the same year.